Stock market announcements Archive - Page 22 of 27

LIFE: Lifecare (Life) recieves regulatory approval for first-in-human Clinical Pilot Evaluation

February 15, 2021
Bergen, February 15th, 2021 - Lifecare AS (LIFE) Lifecare has received regulatory approval for the first-in-human SencellClinical Study Protocol from the German Federal Institute for Drugs and MedicalDevices (BfArM). With this final remaining approval, Lifecare has reached itsgoal to have clinical pilot trial permission as planned in Q1 2021. Lifecare CEO Joacim Holter says, "With […]
Read more

LIFE: Financial calendar

February 15, 2021
Financial calendar for Lifecare ASFINANCIAL YEAR 202105.08.2021 - Half-yearly Report20.04.2021 - Annual Report07.05.2021 - Annual General MeetingThis information is published pursuant to the requirements set out in theContinuing obligations.
Read more

LIFE: Finansiell kalender

February 15, 2021
Finansiell kalender for Lifecare ASREGNSKAPSÅR 202105.08.2021 - Halvårsrapport20.04.2021 - Årsrapport07.05.2021 - Ordinær generalforsamlingDenne informasjonen offentliggjøres i henhold til kravene i Løpendeforpliktelser.
Read more

Regarding Share Transfere AGreement Human Data – Evergreen 20.10.20

October 20, 2020
Stock Market announcement Bergen, Norway – October 20, 2020: The Norwegian listed company Lifecare AS (LIFE-ME) has a 25% ownership in the German company Digital Diagnostics AG, which has developed an accurate and reliable rapid test for Covid-19. Bionovate Technologies Corp. (BIIO), a swiss based company traded at Nasdaq OTC Foreign, has announced a Share […]
Read more

Vedr aksjebytte avtale Human Data – Evergreen 20.10.20

October 20, 2020
Bergen – 20. oktober 2020: Lifecare AS (LIFE-ME) eier 25% av Digital Diagnostics AG, som har utviklet en hurtigtest for Covid-19. Bionovate Technologies Corp. (BIIO), et sveitsisk basert selskap notert som Nasdaq OTC Foreign, har annonsert aksjebytteavtale mellom Evergreen Solutions Ltd. og Human Data AG til United States Securities and Exchange Commission. Aksjebytteavtalen omfatter ifølge […]
Read more

Lifecare – klargjøring vedr kjerneteknologi – 13.10.20

October 13, 2020
Som følge av verdifall for Lifecares (LIFE-ME) aksjer på Oslo Børs/Merkur Market mandag 12. oktober 2020 har selskapet mottatt spørsmål fra en rekke aksjonerer og ønsker å formidle følgende: Det er ingen endringer knyttet til Lifecares patenterte sensorteknologi, Sencell, verken alene eller knyttet til samarbeid med våre partnere Digital Diagnostics AG eller prosjektet FORGETDIABETES. Den […]
Read more

Lifecare – clearification regarding core technology 13.10.20

October 13, 2020
Following the value decrease of the Lifecare (LIFE-ME) share at Oslo Stock Exchange/Merkur Market Monday 12 October 2020 the company has received questions from shareholders and wants to clarify: There are no changes in relation to Lifecare’s patented core sensor technology, Sencell, either alone or in relation to our partners Digital Diagnostics AG or the […]
Read more

LIFE-ME: Lifecare deltar i forskningsprosjekt som er tildelt 43 mill i EU-støtte til utvikling av kunstig bukspyttkjertel

October 5, 2020
Lifecare (LIFE-ME) er et Bergensk teknologiselskap som forsker og utvikler en miniatyrisert sensor for korrekt og kontinuerlig overvåking av blodsukker for diabetikere. Selskapets patenterte teknologi anvendes i tillegg som sentral komponent ved utvikling av antigen hurtigtest for Covid-19 og måleenhet for avlesning av forskjellige biomarkører. I samarbeid med seks akademiske partnere i Italia, Frankrike og […]
Read more

Lifecare participating in research project awarded EUR 3,9 million from the EU Commission for development …(Note: This headline has been truncated)

October 5, 2020
Lifecare participating in research project awarded EUR 3,9 million from the EU Commission for development of a bionic invisible pancreas to FORGETDIABETES. Lifecare (LIFE-ME) is a Bergen-based technology company developing a miniature sensor for correct and continuous monitoring of diabetics’ blood sugar. Its patented technology is also used as a central component in a rapid […]
Read more

LIFE-ME: Lifecare AS (LIFE-ME) Increase of share capital following exercise of share option program and share sale by close associate to primary insider

September 25, 2020
Reference is made to the stock exchange announcement by Lifecare AS (the Company) August 6th, 2020 regarding the exercise of 325.826 share options with a strike price of NOK 0,40 per share option, by Islay Venture GmbH - a company controlled by the Company CSO Prof. Dr. Dr. med Andreas Pfützner. Based on authorization granted […]
Read more